Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals

被引：0
|
作者：
Jagpreet Chhatwal
Tianhua He
Maria A. Lopez-Olivo
机构：
[1] Harvard Medical School,Institute for Technology Assessment, Massachusetts General Hospital
[2] Tsinghua University School of Medicine,Department of General Internal Medicine
[3] The University of Texas,undefined
[4] MD Anderson Cancer Center,undefined
来源：
PharmacoEconomics | 2016年 / 34卷
关键词：
Sustained Virological Response Rate; Telaprevir; Sofosbuvir; Boceprevir; Consolidate Health Economic Evaluation Reporting Standard;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：551 / 567
页数：16
相关论文
共 50 条
  • [41] Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
    Abad, Soraya
    Vega, Almudena
    Rincon, Diego
    Hernandez, Eduardo
    Merida, Evangelina
    Macias, Nicolas
    Munoz, Raquel
    Milla, Monica
    Luno, Jose
    Manuel Lopez-Gomez, Juan
    NEFROLOGIA, 2017, 37 (02): : 158 - 163
  • [42] Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance
    Miguel Jiménez-Pérez
    Rocío González-Grande
    Pilar Espa?a Contreras
    Isabel Pinazo Martínez
    Jesús de la Cruz Lombardo
    Raúl Olmedo Martín
    World Journal of Gastroenterology, 2016, 22 (29) : 6573 - 6581
  • [43] Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)
    Peiffer, Kai-Henrik
    Zeuzem, Stefan
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2022, 65 (02) : 246 - 253
  • [44] Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C
    Juanbeltz, R.
    Zozaya, J. M.
    Reparaz, J.
    Castilla, J.
    Sarobe, M. T.
    Otano, J. I. Uriz
    de Alda, M. Gracia Ruiz
    Miguel, R. San
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2017, 40 (01) : 57 - 66
  • [45] Therapy completion of direct-acting antivirals for hepatitis C
    Machado, Marina A. A.
    Moura, Cristiano S.
    Klein, Marina
    Carleton, Bruce
    Winthrop, Kevin
    Abrahamowicz, Michal
    Feld, Jordan
    Curtis, Jeffrey R.
    Bernatsky, Sasha
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 498 - 499
  • [46] Direct-acting antivirals for RSV treatment, a review
    Bonneux, Brecht
    Jacoby, Edgar
    Ceconi, Martina
    Stobbelaar, Kim
    Delputte, Peter
    Herschke, Florence
    ANTIVIRAL RESEARCH, 2024, 229
  • [47] SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRALS TREATMENT FOR ELDERLY CHRONIC HEPATITIS C PATIENTS: A COST-EFFECTIVENESS ANALYSIS
    Ciaccio, A.
    Cortesi, P. A.
    Bellelli, G.
    Rota, Matteo
    Rota, Monica
    Okolicsanyi, S.
    Mantovani, L. G.
    Annoni, G.
    Strazzabosco, M.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S639 - S639
  • [48] THE COST-EFFECTIVENESS OF THE NEW DIRECT ACTING ANTIVIRALS IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 AND GENOTYPE 4: A SYSTEMATIC REVIEW
    Alowairdhi, M.
    VALUE IN HEALTH, 2017, 20 (05) : A183 - A183
  • [49] Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era
    Cacoub, Patrice
    Vautier, Mathieu
    Desbois, Anne Claire
    Lafuma, Antoine
    Saadoun, David
    LIVER INTERNATIONAL, 2017, 37 (12) : 1805 - 1813
  • [50] A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease
    Maruyama, Anna
    Partovi, Nilufar
    Yoshida, Eric M.
    Erb, Siegfried R.
    Azalgara, Vladimir Marquez
    Hussaini, Trana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (01) : 35 - 41
12345